Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints
Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity ass...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Peters, Max [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells - Han, Xiaobing ELSEVIER, 2021, journal of the European Society for Therapeutic Radiology and Oncology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:117 ; year:2015 ; number:2 ; pages:262-269 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.radonc.2015.08.018 |
|---|
| Katalog-ID: |
ELV01280407X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV01280407X | ||
| 003 | DE-627 | ||
| 005 | 20230623101938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.radonc.2015.08.018 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015004000002.pica |
| 035 | |a (DE-627)ELV01280407X | ||
| 035 | |a (ELSEVIER)S0167-8140(15)00443-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 100 | 1 | |a Peters, Max |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints |
| 264 | 1 | |c 2015 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here. | ||
| 650 | 7 | |a Total salvage |2 Elsevier | |
| 650 | 7 | |a Focal salvage |2 Elsevier | |
| 650 | 7 | |a Dosimetry |2 Elsevier | |
| 650 | 7 | |a I125 brachytherapy |2 Elsevier | |
| 650 | 7 | |a GU toxicity |2 Elsevier | |
| 650 | 7 | |a Prostate cancer |2 Elsevier | |
| 700 | 1 | |a van der Voort van Zyp, Jochem |4 oth | |
| 700 | 1 | |a Hoekstra, Carel |4 oth | |
| 700 | 1 | |a Westendorp, Hendrik |4 oth | |
| 700 | 1 | |a van de Pol, Sandrine |4 oth | |
| 700 | 1 | |a Moerland, Marinus |4 oth | |
| 700 | 1 | |a Maenhout, Metha |4 oth | |
| 700 | 1 | |a Kattevilder, Rob |4 oth | |
| 700 | 1 | |a van Vulpen, Marco |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Han, Xiaobing ELSEVIER |t Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |d 2021 |d journal of the European Society for Therapeutic Radiology and Oncology |g Amsterdam [u.a.] |w (DE-627)ELV00004122X |
| 773 | 1 | 8 | |g volume:117 |g year:2015 |g number:2 |g pages:262-269 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.radonc.2015.08.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 117 |j 2015 |e 2 |h 262-269 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
m p mp |
|---|---|
| matchkey_str |
petersmaxvandervoortvanzypjochemhoekstra:2015----:rtrlnbadroierottlnfclavgidn15rsaercyhrpl |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
10.1016/j.radonc.2015.08.018 doi GBVA2015004000002.pica (DE-627)ELV01280407X (ELSEVIER)S0167-8140(15)00443-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Peters, Max verfasserin aut Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here. Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer Elsevier van der Voort van Zyp, Jochem oth Hoekstra, Carel oth Westendorp, Hendrik oth van de Pol, Sandrine oth Moerland, Marinus oth Maenhout, Metha oth Kattevilder, Rob oth van Vulpen, Marco oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:117 year:2015 number:2 pages:262-269 extent:8 https://doi.org/10.1016/j.radonc.2015.08.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 117 2015 2 262-269 8 045F 610 |
| spelling |
10.1016/j.radonc.2015.08.018 doi GBVA2015004000002.pica (DE-627)ELV01280407X (ELSEVIER)S0167-8140(15)00443-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Peters, Max verfasserin aut Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here. Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer Elsevier van der Voort van Zyp, Jochem oth Hoekstra, Carel oth Westendorp, Hendrik oth van de Pol, Sandrine oth Moerland, Marinus oth Maenhout, Metha oth Kattevilder, Rob oth van Vulpen, Marco oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:117 year:2015 number:2 pages:262-269 extent:8 https://doi.org/10.1016/j.radonc.2015.08.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 117 2015 2 262-269 8 045F 610 |
| allfields_unstemmed |
10.1016/j.radonc.2015.08.018 doi GBVA2015004000002.pica (DE-627)ELV01280407X (ELSEVIER)S0167-8140(15)00443-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Peters, Max verfasserin aut Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here. Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer Elsevier van der Voort van Zyp, Jochem oth Hoekstra, Carel oth Westendorp, Hendrik oth van de Pol, Sandrine oth Moerland, Marinus oth Maenhout, Metha oth Kattevilder, Rob oth van Vulpen, Marco oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:117 year:2015 number:2 pages:262-269 extent:8 https://doi.org/10.1016/j.radonc.2015.08.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 117 2015 2 262-269 8 045F 610 |
| allfieldsGer |
10.1016/j.radonc.2015.08.018 doi GBVA2015004000002.pica (DE-627)ELV01280407X (ELSEVIER)S0167-8140(15)00443-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Peters, Max verfasserin aut Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here. Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer Elsevier van der Voort van Zyp, Jochem oth Hoekstra, Carel oth Westendorp, Hendrik oth van de Pol, Sandrine oth Moerland, Marinus oth Maenhout, Metha oth Kattevilder, Rob oth van Vulpen, Marco oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:117 year:2015 number:2 pages:262-269 extent:8 https://doi.org/10.1016/j.radonc.2015.08.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 117 2015 2 262-269 8 045F 610 |
| allfieldsSound |
10.1016/j.radonc.2015.08.018 doi GBVA2015004000002.pica (DE-627)ELV01280407X (ELSEVIER)S0167-8140(15)00443-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 540 VZ Peters, Max verfasserin aut Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints 2015 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here. Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer Elsevier van der Voort van Zyp, Jochem oth Hoekstra, Carel oth Westendorp, Hendrik oth van de Pol, Sandrine oth Moerland, Marinus oth Maenhout, Metha oth Kattevilder, Rob oth van Vulpen, Marco oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:117 year:2015 number:2 pages:262-269 extent:8 https://doi.org/10.1016/j.radonc.2015.08.018 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 117 2015 2 262-269 8 045F 610 |
| language |
English |
| source |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:117 year:2015 number:2 pages:262-269 extent:8 |
| sourceStr |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:117 year:2015 number:2 pages:262-269 extent:8 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Total salvage Focal salvage Dosimetry I125 brachytherapy GU toxicity Prostate cancer |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| authorswithroles_txt_mv |
Peters, Max @@aut@@ van der Voort van Zyp, Jochem @@oth@@ Hoekstra, Carel @@oth@@ Westendorp, Hendrik @@oth@@ van de Pol, Sandrine @@oth@@ Moerland, Marinus @@oth@@ Maenhout, Metha @@oth@@ Kattevilder, Rob @@oth@@ van Vulpen, Marco @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00004122X |
| dewey-sort |
3610 |
| id |
ELV01280407X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV01280407X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623101938.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2015.08.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015004000002.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV01280407X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(15)00443-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Peters, Max</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Total salvage</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Focal salvage</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dosimetry</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">I125 brachytherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GU toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Voort van Zyp, Jochem</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoekstra, Carel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Westendorp, Hendrik</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van de Pol, Sandrine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moerland, Marinus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maenhout, Metha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kattevilder, Rob</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Vulpen, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:117</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:262-269</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2015.08.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">117</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">262-269</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Peters, Max |
| spellingShingle |
Peters, Max ddc 610 ddc 570 Elsevier Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints |
| authorStr |
Peters, Max |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00004122X |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 570 540 VZ Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer Elsevier |
| topic |
ddc 610 ddc 570 Elsevier Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer |
| topic_unstemmed |
ddc 610 ddc 570 Elsevier Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer |
| topic_browse |
ddc 610 ddc 570 Elsevier Total salvage Elsevier Focal salvage Elsevier Dosimetry Elsevier I125 brachytherapy Elsevier GU toxicity Elsevier Prostate cancer |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
d v v z j v dvvzj dvvzjv c h ch h w hw d p s v dps dpsv m m mm m m mm r k rk v m v vm vmv |
| hierarchy_parent_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| hierarchy_parent_id |
ELV00004122X |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00004122X |
| title |
Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints |
| ctrlnum |
(DE-627)ELV01280407X (ELSEVIER)S0167-8140(15)00443-0 |
| title_full |
Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints |
| author_sort |
Peters, Max |
| journal |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| journalStr |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
262 |
| author_browse |
Peters, Max |
| container_volume |
117 |
| physical |
8 |
| class |
610 610 DE-600 570 540 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Peters, Max |
| doi_str_mv |
10.1016/j.radonc.2015.08.018 |
| dewey-full |
610 570 540 |
| title_sort |
urethral and bladder dosimetry of total and focal salvage iodine-125 prostate brachytherapy: late toxicity and dose constraints |
| title_auth |
Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints |
| abstract |
Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here. |
| abstractGer |
Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here. |
| abstract_unstemmed |
Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
2 |
| title_short |
Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints |
| url |
https://doi.org/10.1016/j.radonc.2015.08.018 |
| remote_bool |
true |
| author2 |
van der Voort van Zyp, Jochem Hoekstra, Carel Westendorp, Hendrik van de Pol, Sandrine Moerland, Marinus Maenhout, Metha Kattevilder, Rob van Vulpen, Marco |
| author2Str |
van der Voort van Zyp, Jochem Hoekstra, Carel Westendorp, Hendrik van de Pol, Sandrine Moerland, Marinus Maenhout, Metha Kattevilder, Rob van Vulpen, Marco |
| ppnlink |
ELV00004122X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.radonc.2015.08.018 |
| up_date |
2024-07-06T17:14:03.903Z |
| _version_ |
1803850658772680704 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV01280407X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623101938.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2015.08.018</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015004000002.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV01280407X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(15)00443-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Peters, Max</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Salvage Iodine-125 brachytherapy (I-125-BT) constitutes a curative treatment approach for patients with organ-confined recurrent prostate cancer after primary radiotherapy. Currently, focal salvage (FS) instead of whole-gland or total salvage (TS) is being investigated, to reduce severe toxicity associated with cumulative radiation dose. Differences in urethral and bladder dosimetry and constraints to reduce late (>90days) genitourinary (GU) toxicity are presented here.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Total salvage</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Focal salvage</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Dosimetry</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">I125 brachytherapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">GU toxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Prostate cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Voort van Zyp, Jochem</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hoekstra, Carel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Westendorp, Hendrik</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van de Pol, Sandrine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moerland, Marinus</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Maenhout, Metha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kattevilder, Rob</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van Vulpen, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:117</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:262-269</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2015.08.018</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">117</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">262-269</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400218 |